Concurrent CDX2 cis-deregulation and UBTF-ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

Marie Passet,Rathana Kim,Stéphanie Gachet,François Sigaux,Julie Chaumeil,Ava Galland,Thomas Sexton,Samuel Quentin,Lucie Hernandez,Lise Larcher,Hugo Bergugnat,Tao Ye,Nezih Karasu,Aurélie Caye-Eude,Beate Heizmann,Isabelle Duluc,Patrice Chevallier,Philippe Rousselot,Françoise Huguet,Thibault TL Leguay,Mathilde M Hunault-Berger,Francoise Pflumio,Jean-Noel Freund,Camille Lobry,Veronique Lheritier,Hervé Dombret,Claire Domon-Dell,Jean Soulier,Nicolas Boissel,Emmanuelle Clappier

DOI: https://doi.org/10.1182/blood.2021014723

IF: 20.3

2022-03-22

Blood

Abstract:Oncogenic alterations underlying B-cell acute lymphoblastic leukemia (B-ALL) in adults remain incompletely elucidated. To uncover novel oncogenic drivers, we performed RNA-seq and whole-genome analyses in a large cohort of unresolved B-ALL. We identified a novel subtype characterized by a distinct gene expression signature and the unique association of two genomic microdeletions. The 17q21.31 microdeletion resulted in a UBTF::ATXN7L3 fusion transcript encoding a chimeric protein. The 13q12.2 deletion resulted in monoallelic ectopic expression of the homeobox transcription factor CDX2, located 138 kb in cis from the deletion. Using 4C-seq and CRISPR interference experiments, we elucidated the mechanism of CDX2 cis-deregulation, involving PAN3 enhancer hijacking. CDX2/UBTF ALL (n=26) harbored a distinct pattern of additional alterations including 1q gain and CXCR4 activating mutations. Within adult patients with Ph-negative B-ALL enrolled in GRAALL trials, patients with CDX2/UBTF ALL (n=17/723, 2.4%) were frequently young women (M/F ratio 0.2, P=0.002, median age 31 years). They commonly presented with a pro-B phenotype ALL and moderate blast cell infiltration. They had poor response to treatment including a higher risk of failure to first induction course (19% versus 3%, P=0.017) and higher post-induction MRD levels (MRD ≥ 10-4, 93%, versus 46%, P<0.001). This early resistance to treatment translated into a significantly higher cumulative incidence of relapse (75.0% versus 32.4%, P=0.004) in univariate and multivariate analyses. In conclusion, we discovered a novel B-ALL entity defined by the unique combination of CDX2 cis-deregulation and UBTF::ATXN7L3 fusion, representing a high-risk disease in young adults. Study can be found on https://clinicaltrials.gov NCT00327678 and NCT02617004.

hematology